Provided by Tiger Trade Technology Pte. Ltd.

Cognition Therapeutics, Inc

0.9959
+0.03924.10%
Post-market: 1.010.0141+1.42%19:30 EDT
Volume:308.33K
Turnover:305.66K
Market Cap:94.70M
PE:-5.14
High:1.01
Open:0.9750
Low:0.9699
Close:0.9567
52wk High:3.83
52wk Low:0.5501
Shares:95.09M
Float Shares:85.42M
Volume Ratio:0.63
T/O Rate:0.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1936
EPS(LYR):-0.3228
ROE:-83.76%
ROA:-78.18%
PB:2.87
PE(LYR):-3.09

Loading ...

Soligenix Q2 Net Loss Narrows as R&D Expenses Fall

Reuters
·
Aug 07

Cognition Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 07

Cognition Therapeutics reports Q2 EPS (4c), consensus (6c)

TIPRANKS
·
Aug 07

Cognition Therapeutics Q2 EPS $(0.04) Beats $(0.06) Estimate

Benzinga Earnings
·
Aug 07

Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update

THOMSON REUTERS
·
Aug 07

Cognition Therapeutics Q2 Income from Operations USD -7.738 Million

THOMSON REUTERS
·
Aug 07

Cognition Therapeutics Inc Expected to Post a Loss of 6 Cents a Share - Earnings Preview

Reuters
·
Aug 03

Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Invest In Growth?

Simply Wall St.
·
Jul 16

Cognition Therapeutics Posts Press Release on B. Riley Summit Fireside Chat to IR Website

Reuters
·
Jul 13

H.C. Wainwright Keeps Their Buy Rating on Cognition Therapeutics (CGTX)

TIPRANKS
·
Jun 25

Cognition Therapeutics gets FDA feedback on zervimesine study

TIPRANKS
·
Jun 24

Cognition Therapeutics Targets Mid-2027 Start for Phase 3 Zervimesine Trial in DLB Psychosis

Reuters
·
Jun 24

Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (ct1812) in Dlb Psychosis Following Receipt of FDA Meeting Minutes

THOMSON REUTERS
·
Jun 24

Cognition Therapeutics - Registrational Program for Zervimesine in Dlb Psychosis to Begin Mid-2027

THOMSON REUTERS
·
Jun 24

Cognition Therapeutics - to Use Neuropsychiatric Inventory as Primary Endpoint in Pivotal Dlb Psychosis Trial

THOMSON REUTERS
·
Jun 24

H.C. Wainwright Reaffirms Their Buy Rating on Cognition Therapeutics (CGTX)

TIPRANKS
·
Jun 22

Cognition Therapeutics Shareholders Elect Directors, Ratify Auditor

TIPRANKS
·
Jun 18

Cognition Therapeutics shareholders elect Aaron Fletcher, Lisa Ricciardi as Class II directors

Reuters
·
Jun 18

Cognition Therapeutics Receives Patent Allowance for Polymorphic Crystalline Form of Zervimesine

MT Newswires Live
·
Jun 16

Cognition Therapeutics says USPTO allows zervimesine patent application extending protection to 2045

Reuters
·
Jun 16